Illumina made a strategic investment in MyOme and will supply sequencing for a prospective trial testing whole‑genome sequencing combined with AI risk models to improve population health outcomes. MyOme’s Proactive Health (MPH) study will pair Illumina NovaSeq X sequencing with AI‑integrated polygenic and rare‑variant models to evaluate clinical utility, cost‑savings and downstream interventions. MyOme CEO Premal Shah framed the effort as an attempt to demonstrate economic benefit by enabling earlier, actionable risk detection for common chronic conditions. Illumina termed the deal alignment with its multiomic strategy and signalled support for integrating genomics into population health. Observers noted that the trial’s design, endpoints and reimbursement strategy will be pivotal to determine if WGS+AI can scale beyond niche high‑risk populations. The partnership underscores commercial sequencing vendors’ pivot from instruments to end‑to‑end clinical value propositions, and will be closely watched by payers and health systems evaluating genomic screening programs.